Innovation Pharmaceuticals’ COVID-19 Clinical Tr
Post# of 72440
(Total Views: 507)
Posted On: 10/25/2021 7:51:35 AM
Innovation Pharmaceuticals’ COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
Brilacidin
WAKEFIELD, MA / October 25, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline results the week of November 8th from its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The study data is presently blinded at the data management vendor, with final checks and approvals in progress.
Brilacidin
WAKEFIELD, MA / October 25, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline results the week of November 8th from its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The study data is presently blinded at the data management vendor, with final checks and approvals in progress.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Ronald A Phillips
Scroll down for more posts ▼